Dartmouth Cancer Center has appointed Roy S. Herbst, MD, PhD, as its sixth director. Herbst will lead integrated efforts to strengthen cancer research, education, and collaboration across Dartmouth and Dartmouth Health, expand access to advanced treatments and clinical trials, and continue to elevate cancer care throughout New England and beyond.
Herbst is internationally recognized as a pioneer in the development of targeted and immune-based therapies for the treatment of lung cancer. He joins the Cancer Center from Yale University, where he has served as deputy director and chief of medical oncology and hematology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut.
Herbst has helped shape modern cancer research, leading a shift to increasingly personalize therapeutic approaches and to expand the use of targeted therapies during the earliest stages of disease. His trailblazing work in the field of lung cancer has contributed to the approval of multiple therapies that are now the standard of care, and he continues to advance research focused on earlier detection and treatment.
In addition to his research and clinical leadership, Herbst is a dedicated educator, mentor, and advocate. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. He is the recipient of the International Association for the Study of Lung Cancer (IASLC) Paul Bunn Scientific Award for his contributions to lung cancer care and research, and the American Association for Cancer Research Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy.